Proud to Serve as a Living Red Sponsor for the 2024 ADA Step Out Walk in Long Beach, CA
San Diego, August 15, 2024 — ProSciento, Inc., a leading clinical research organization specializing in metabolic diseases, proudly marks 20 years of support for the American Diabetes Association (ADA) and its mission to prevent and cure diabetes and improve the lives of those affected by it. In continued partnership with the ADA, ProSciento will serve as a Living Red Sponsor of the 2024 Step Out: Walk to Stop Diabetes in Long Beach, California on October 26, 2024.
The Living Red Sponsor designation honors companies that actively champion the diabetes community by supporting individuals who live with diabetes every day—those who “live red.” These participants wear red at the walk to symbolize their strength and resilience, and the sponsor role reflects ProSciento’s ongoing commitment to standing with them.
“For two decades, our work has been driven by the goal of improving the lives of people living with diabetes,” said Dr. Marcus Hompesch, CEO of ProSciento. “We are honored to partner with the American Diabetes Association and support initiatives like the Step Out Walk that not only raise critical funds for research and also celebrate and empower those affected by diabetes. The Living Red Sponsor role is especially meaningful to us—it’s a reminder of why this work matters.”
Since 2004, ProSciento has contributed time, resources, and funding to ADA programs and events across Southern California. ProSciento looks forward to building on this legacy of support and walking alongside patients, families, researchers, and advocates in the fight against diabetes.
About ProSciento
ProSciento is the leading provider of clinical research and patient engagement solutions for metabolic continuum diseases with unparalleled expertise in diabetes, obesity, and steatotic liver disease. As a full-service clinical research organization (CRO), ProSciento works with clients of all sizes worldwide to design and conduct multinational clinical trials, from early clinical development planning through phase III. With two decades as a leading scientific contributor to metabolic continuum research, ProSciento has trusted relationships with clients, partners, and patients, supporting the development of therapeutics and devices that make an important difference in the lives of individuals with metabolic diseases. For more information, please visit www.prosciento.com.